Article

Increasing prevalence of ocular MRSA noted

The rate of methicillin-resistant Staphylococcus aureus (MRSA) is increasing in both systemic and ocular infections, according to an analysis of nationwide surveillance data. Increasing rates of resistance and lowered rates of susceptibility could soon reduce the number of drugs that can be successfully used to treat ocular infections.

Among S aureus isolates from a variety of clinical specimens, MRSA prevalence has increased from 29.5% in 2000 to 41.6% in 2005, and a 12.1% increase in MRSA among S aureus isolates from ocular sources was seen during the same period, Dr. Asbell said. She and colleagues from an independent laboratory analyzed nationwide surveillance data and summarized their findings in a poster at the American Academy of Ophthalmology meeting in November.

The data, collected from several hundred institutions over a 5-year period, showed an increasing level of resistance, with the percentage of MRSA potentially surpassing that of methicillin-susceptible S aureus (MSSA) by 2008, Dr. Asbell said, adding that this trend will have implications in the ophthalmology community as well as in medicine as a whole.

Antimicrobial susceptibility

The study also analyzed the antimicrobial susceptibility of ocular S aureus based on methicillin status from 2004 to September 2006. For every agent except trimethoprim, MRSA susceptibility is substantially lower than MSSA susceptibility. The agents tested included ciprofloxacin (Ciloxan, Alcon Laboratories), gatifloxacin (Zymar, Allergan), levofloxacin (Quixin, Vistakon), penicillin, polymyxin B, tobramycin (Tobrex, Alcon), and trimethoprim.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.